04.10.2018

Alvimedica NiTiDES @ CIRSE 2018

öffnen
NiTiDES is a polymer free stent-eluting the amphilimus formulation (a combination of sirolimus and fatty acid) through the “Abluminal Reservoir Technology” aiming at obtaining the highest efficacy profile for the patient

Alvimedica NiTiDES @ CIRSE 2018

NiTiDES is a polymer free stent-eluting the amphilimus formulation (a combination of sirolimus and fatty acid) through the “Abluminal Reservoir Technology” aiming at obtaining the highest efficacy profile for the patient. The polymer-free platform, which is made of nitinol, is integrally covered by the Bio Inducer Surface coating, a second generation pure carbon “ultra thin” layer that drastically increases haemo- and biocompatibility.

Alvimedica NiTiDES – Platform characteristics / Dr. Ralf Langhoff, St. Gertrauden Hospital, Berlin

ILLUMINA Study – NiTiDES First In Human Trial / Prof. Dr. Dierk Scheinert, University Hospital Leipzig

Watch the complete Satellite Symposium @ CIRSE Library

02.05.2018

luminor – The best DCB ever!

öffnen
EFFPAC RCT 12-month outstanding results with Luminor DCB have been revealed at CX Symposium 2018.

EFFPAC RCT 12-month outstanding results with Luminor DCB have been revealed at CX Symposium 2018

London, April 25th, 2018 – EFFPAC RCT 12-month outstanding results with Luminor DCB have been revealed at CX Symposium 2018.

The 12-month results from the full clinical cohort of the EFFPAC randomized controlled trial (RCT), were presented for the first time at CX Symposium 2018 at the DCB session on April 24th.

Main objective was to assess the effectiveness of Luminor drug coated balloon (DCB) vs. Uncoated balloon catheter (POBA), in the superficial femoral and popliteal arteries. The EFFPAC RCT 12-month outcomes are all demonstrating high statistical significance versus POBA, therefore confirming and even maintaining, the already excellent 6-month outcomes:

To view the complete presentation from Prof. Teichgräber @ about EFFPAC trial at CharingX 2018
<< CLICK HERE >>

  • Late Lumen Loss (LLL) at 6 months: 0.14mm
  • Target Lesion Revascularization (TLR) at 12 months: 1.3%
  • Primary Patency (PP) at 12 months: 90.3%
  • Rutherford stage improvement at 12 month: 90.6%